Navigation Links
Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia
Date:6/29/2009

lly bioavailable agent might expand usage and improve patient compliance as well.

"This sooner than expected start of preclinical development studies is an affirmation of CrystalGenomics' capability to discover novel drug candidates in an efficient way and through shared responsibilities with Palkion, we will accelerate our drug development process and establish CG as a global-scale pharmaceutical firm," stated Dr. Joong-Myung Cho, President and CEO of CrystalGenomics.

"Excellent progress has been made in our collaboration with CrystalGenomics. We have now assembled an outstanding team to progress our lead candidate toward the clinic," stated Wendy Johnson, President and CEO of Palkion.

About Palkion: Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on discovery and development of oral agents that inhibit prolyl hydroxylase enzymes. The inhibition of these enzymes results in endogenous production of erythropoietin, leading to the production of red blood cells. The use of an oral agent provides convenience and dosing flexibility potentially reaching more patients than the current injectable products. The company was formed by ProQuest Investments and CrystalGenomics, Inc. in February 2008.

About CrystalGenomics: CrystalGenomics, Inc. is a novel drug discovery and development company with several developmental candidates in the areas of cancer, inflammation and novel antibiotics. The lead candidate, CG100649 is a next generation NSAID with high safety and efficacy, which recently completed phase IIa of 248 patients for osteoarthritis in Europe. CG200745 is an oral/IV HDAC inhibitor for cancer and CG400549 is a novel antibiotic against MRSA and VRSA, both of which are in pre-clinical studies in Europe. The company has competitive and proprietary platform technologies for structural biology, structure-based novel scaffold/lead design, lead optimization a
'/>"/>

SOURCE Palkion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service
2. HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists Choice Award for Best New Separations Product in 2008
3. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
4. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
5. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
6. USAID Selects Abt Associates to Lead Team in Strengthening Mexico Private Sector Competitiveness
7. The Australian Research Council Selects Scopus for the Evaluation of the Australian Research Landscape
8. Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009
9. The IN VIVO Blog Selects First Annual Deal of the Year
10. Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians
11. WuXi AppTec Selects H-Cube from ThalesNano for Laboratory-based Hydrogenation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue: India Solid Waste Management ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... main governing bodies responsible for complete handling and ... an average, around 135,000 MT solid waste is ...
(Date:9/1/2014)... September 01, 2014 The Collaborative ... Diagnostics report provides comprehensive understanding and unprecedented access ... into by the worlds leading life science companies. ... analysis of how and why companies enter collaborative ... prospective partner’s negotiated deals terms provides critical insight ...
(Date:8/31/2014)... 2014 Available spectra is similar ... research and cultivation of a wide range of ... LEDs with proven patented and pending wide spectrum ... uniformity in critical applications in contrast to growth ... “Our customers have a large variety of differently ...
(Date:8/31/2014)... This is a professional and in-depth ... Hardener industry in Global and China. The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
Breaking Biology Technology:India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3
... Identify Potential Initiation Dosing Regimen , ... palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant ... of a 13-week study presented today (1). Statistical ... and 150 mg equivalent [eq.a]), when given every 4 ...
... the Journal Blood for the American Society of Hematology Annual ... Dec. 10 Alfacell Corporation (Nasdaq: ACEL ) ... abstracts in Blood (2008 112: Abstract 4205 & ... (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia (CLL) and ...
... Calif., Dec. 10 Valeant,Pharmaceuticals International (NYSE: ... signed a,definitive agreement to acquire Dow Pharmaceutical Sciences, ... the development of topical,products on a proprietary basis, ... The transaction significantly enhances Valeant,s,dermatology franchise in the ...
Cached Biology Technology:Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 2Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 3Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 4Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 5Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 6Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 7Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 8Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 9Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 2Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 3Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 4Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 5
(Date:9/2/2014)... Passerine birds, also known as perching birds, that migrate ... they do in autumn to reach their destinations. This ... birds that only make short migratory flights, says researcher ... journal Behavioral Ecology and Sociobiology . , ... used a tracking radar to measure over three years ...
(Date:9/2/2014)... Air pollution regulations over the last decade in Taiyuan, ... there, accounting for a greater than 50% reduction in ... 2001 and 2010, according to researchers at the Columbia ... School of Public Health, the Shanxi Medical University, the ... and Shanghai Fudan University School of Public Health. , ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
Breaking Biology News(10 mins):Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... speech President Bush said technology is the best way to ... Energy Joint Genome Institute (DOE JGI) is directing the technology ... will lead to cheaper and easier to produce biofuels. ... molecular biology we can generate diagnostic fingerprints, Environmental Genomic Tags ...
... the March 24 Cell reports the discovery of a ... could offer a potential new target for countermeasures against ... therapies might have the potential to protect against anthrax ... have lost their therapeutic value, they added. , The ...
... Scientists have for many years debated the cause of ... Papagrigorakis and colleagues using DNA collected from teeth from ... as the disease responsible for this devastating epidemic. The ... Journal of Infectious Diseases (IJID) published by Elsevier on ...
Cached Biology News:Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy 2Driver of anthrax toxicity could lead to late-stage therapy 2Typhoid fever led to the fall of Athens 2
... Reagents are complete ready-to-use reagents for the ... is specifically formulated for the isolation of ... is specifically formulated for the isolation of ... with DNAzol Reagents can be used for ...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: